{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 42,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "before_after",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "Uses a before-after-bridge structure to frame the problem (poor outcomes) and the solution (Capivasertib).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/36",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.53,
        "y": 0.78
      },
      "kind": "callout",
      "text": "CAPItello-291 regulatory submission planned H1 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf87d092-ed75-4fb2-b689-ded0b4ec9ec8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.53,
        "y": 0.34
      },
      "kind": "list",
      "text": "CAPItello-291 overcomes key mechanism of ET + CDK4/6i resistance; reflects clinical practice; Clinically meaningful in the overall population (mPFS improvement 3.6 to 7.2 months); Compelling safety and tolerability profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "116d20e1-e372-40ee-a67b-d7ed1c7a0a72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.06,
        "y": 0.34
      },
      "kind": "list",
      "text": "75,000 patients diagnosed each year with metastatic Breast Cancer; Rapid progression following 1L SoC; 65,000 new 2L patients each year; Lack of clear SoC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5114b8d6-8089-4d35-b230-77918e25630b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.53,
        "y": 0.275
      },
      "kind": "paragraph",
      "text": "Capivasertib addresses key unmet need",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "818f220f-f681-41fe-a662-19c14c86c492",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.06,
        "y": 0.275
      },
      "kind": "paragraph",
      "text": "Patient outcomes in 2L+ mBC remain poor",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd599329-b6c5-4525-8907-cb808796f43e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1 US, EU and JP; 2 Across G7 countries; AKT = a serine/threonine protein kinase; mBC = metastatic breast cancer; CDK4/6i = cyclin-dependent kinase 4/6 inhibitors; SoC = standard of care; ER-driven = oestrogen receptor driven; ET = endocrine therapy; mPFS = median progression free survival; HR = hazard ratio.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "925af4a6-5760-4b99-9273-ed2aec5c259f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Capivasertib first-in-class AKT inhibitor, addresses unmet need in 2L+ mBC",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "081499bb-f12c-4092-87d1-4a110bd67497",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "CAPItello-291: potential new standard of care",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec8def0f-7fd9-49a5-a8a4-a45ba53e92ab",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "80c26d8f-b087-4a81-b820-d69d2434580d",
      "evidence": "The slide identifies a problem (poor patient outcomes in 2L+ mBC), agitates it by highlighting the unmet need, and offers a solution (Capivasertib as a potential new standard of care).",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "0c4276bc-3a04-4a56-8c3e-23ceda4b8e27",
      "evidence": "Contrasts poor patient outcomes (problem) with Capivasertib's clinical benefits (solution).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 37,
      "from": 30,
      "beatId": "88b7703b-c29f-499c-87c5-dd04e5a0e55a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Other key data, Enhertu, and capivasertib",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 34,
      "name": "Confession",
      "slug": "22-confession",
      "bestFor": "Crisis communication, rebuilding trust, authenticity marketing",
      "matchId": "b58a08dc-4e91-457f-a2e1-8907740ea80a",
      "evidence": "Problem statement and customer journey",
      "position": 0,
      "objective": "What is the significant unmet need in breast cancer?",
      "structure": "The Honest Admission -> What We Learned -> How We're Different Now",
      "confidence": 0.7,
      "description": "Build credibility by admitting a weakness or mistake before presenting your strength"
    },
    {
      "to": 36,
      "from": 35,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "e11ba950-46fd-416a-b7b0-47f302af001d",
      "evidence": "Customer journey and problem statement",
      "position": 3,
      "objective": "What are the needs of patients with HR+ Breast Cancer?",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}